Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could removing tubes first, ovaries later prevent ovarian cancer just as well?

NCT ID NCT04294927

Prevention Sponsor: University Medical Center Nijmegen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is for women with BRCA1, BRCA2, or other gene mutations that greatly raise ovarian cancer risk. Instead of removing both ovaries and fallopian tubes at once, researchers are testing whether removing just the tubes first and delaying ovary removal is equally safe. The goal is to see if this two-step approach prevents cancer while avoiding early menopause. About 3,000 women will take part across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could offer a safer, less invasive option for women with high genetic risk of ovarian cancer, preserving ovarian function longer.
What could go wrong
This is a large but non-randomized study; results may take years. There is a risk that delaying ovary removal could allow cancer to develop in the ovaries.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 3,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2020

Expected to finish

Feb 2040

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 50 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women with a class 5 (definitely pathogenic) BRCA1, BRCA2, RAD51C, RAD51D or BRIP1 germline mutation in one of the participating centers. * Age at inclusion; * BRCA1: 25-40 years * BRCA2: 25-45 years * RAD51C, RAD51D, BRIP1: 25-50 years * Childbearing completed * Presence of at least one fallopian tube * Participants may have a personal history of non-ovarian malignancy * Informed consent must be obtained and documented according to national and local regulatory requirements and the local rules followed in the institution. Exclusion Criteria: * Postmenopausal status (natural menopause or due to treatment) * Wish for second stage RRO within two years after RRS * Legally incapable * Prior bilateral salpingectomy * A personal history of ovarian, fallopian tube or peritoneal cancer * Current diagnosis or treatment for malignant disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRCA1 gene mutation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

BRCA2-related cancer predisposition RAD51C-related cancer predisposition RAD51D-related cancer predisposition ovarian cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRCA1 gene mutation BRCA2 gene mutation BRIP1 gene mutation Ovarian cancer RAD51C gene mutation RAD51D gene mutation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    65 sites in 16 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AC Camargo Cancer Centre

    RECRUITING

    São Paulo, Brazil

  • Akershus University Hospital

    ACTIVE_NOT_RECRUITING

    Nordbyhagen, Norway

  • Amphia

    RECRUITING

    Breda, Netherlands

  • Amsterdam University Medical Center

    RECRUITING

    Amsterdam, Netherlands

  • Antoni van Leeuwenhoek

    RECRUITING

    Amsterdam, Netherlands

  • Bonifraterskie Centrum Medyczne

    RECRUITING

    Katowice, Poland

  • Catharina Ziekenhuis

    RECRUITING

    Eindhoven, North Brabant, 5623 EJ, Netherlands

  • Chris O'Brien Lifehouse

    RECRUITING

    Sydney, New South Wales, 2050, Australia

  • Cork University Hospital

    RECRUITING

    Cork, Ireland

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Duke University Hospital

    RECRUITING

    Durham, North Carolina, 27705, United States

  • Elisabeth-TweeSteden Ziekenhuis

    RECRUITING

    Tilburg, North Brabant, Netherlands

  • Epworth Hospital

    RECRUITING

    Richmon, Victoria, 3121, Australia

  • Erasmus Medical Center

    RECRUITING

    Rotterdam, Netherlands

  • Evang. Kliniken Essen-Mitte

    RECRUITING

    Essen, Germany

  • Evangelische Waldkrankenhaus Spandau Berlin

    RECRUITING

    Berlin-Spandau, Germany

  • Frances Perry House

    RECRUITING

    Melbourne, Victoria, 3050, Australia

  • Gdynia Oncology Centre

    RECRUITING

    Gdynia, Poland

  • Gemelli Hospital

    RECRUITING

    Rome, Italy

  • Greenslopes Private Hospital

    RECRUITING

    Brisbane, Queensland, 4120, Australia

  • Harris Health Lyndon B. Johnson Hospital

    RECRUITING

    Houston, Texas, 77026, United States

  • Hopital Universitaire Bruxelles

    RECRUITING

    Brussels, Belgium

  • Hospital Británico

    RECRUITING

    Montevideo, Uruguay

  • Hospital of the University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Humanitas San Pio X

    RECRUITING

    Milan, Italy

  • Instituto Nacional de Cancerología

    RECRUITING

    Mexico City, Mexico

  • Isala Klinieken

    RECRUITING

    Zwolle, Netherlands

  • Karolinksa Institutet

    RECRUITING

    Stockholm, Sweden

  • King Edward Memorial Hospital

    RECRUITING

    Perth, Western Australia, 6008, Australia

  • Klinikum Lippe Detmold

    NOT_YET_RECRUITING

    Detmold, Germany

  • Klinikum St. Marien Amberg

    NOT_YET_RECRUITING

    Amberg, Germany

  • Leiden University Medical Center

    RECRUITING

    Leiden, Netherlands

  • MD Anderson Cancer Centre

    RECRUITING

    Houston, Texas, 77030-4009, United States

  • Maastricht University Medical Center

    RECRUITING

    Maastricht, Limburg, Netherlands

  • Maxima Medical Center

    RECRUITING

    Veldhoven, Netherlands

  • Mayo Clinic

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Medical Center Leeuwarden

    RECRUITING

    Leeuwarden, Netherlands

  • Medical University of Graz

    RECRUITING

    Graz, Austria

  • Medical University of Silesia

    RECRUITING

    Katowice, Poland

  • Medisch Spectrum Twente

    RECRUITING

    Enschede, Netherlands

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

  • Mercy Hospital

    RECRUITING

    Melbourne, Victoria, 3084, Australia

  • Monash Health

    RECRUITING

    Melbourne, Australia

  • Mount Sinai Hospital

    RECRUITING

    New York, New York, 10029, United States

  • National Cancer Institute Warsaw

    RECRUITING

    Warsaw, Poland

  • Oslo University Hospital

    RECRUITING

    Oslo, Norway

  • Peter MacCallum Centre

    RECRUITING

    Melbourne, Australia

  • Radboudumc

    RECRUITING

    Nijmegen, Gelderland, Netherlands

  • Royal Adelaide Hospital

    RECRUITING

    Adelaide, South Australia, 5000, Australia

  • Royal Brisbane Hospital

    RECRUITING

    Brisbane, Queensland, 4006, Australia

  • Royal Womens Hospital

    RECRUITING

    Melbourne, Australia

  • San Gerardo Hospital

    RECRUITING

    Monza, Italy

  • St Andrew War Memorial Hospital

    RECRUITING

    Brisbane, Queensland, 4001, Australia

  • Stavanger Uniersity Hospital

    RECRUITING

    Stavanger, Norway

  • The Mater Hospital

    RECRUITING

    Brisbane, Australia

  • UChicago Medicine

    RECRUITING

    Chicago, Illinois, 60637, United States

  • Universita di Bologna

    RECRUITING

    Bologna, Italy

  • Universitair Ziekenhuis Leuven

    RECRUITING

    Leuven, Belgium

  • University Medical Center Groningen

    RECRUITING

    Groningen, Netherlands

  • University Medical Center Utrecht

    RECRUITING

    Utrecht, Netherlands

  • University of Washington

    RECRUITING

    Seattle, Washington, 98195, United States

  • Vall D'Hebron Barcelona

    RECRUITING

    Barcelona, Spain

  • Vancouver General Hospital

    RECRUITING

    Vancouver, Canada

  • Washington University Medical Center

    RECRUITING

    St Louis, Missouri, 63110, United States

  • Western Health

    RECRUITING

    St Albans, Victoria, 3021, Australia

  • Westmead hospital

    RECRUITING

    Sydney, New South Wales, 2145, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.